Takeda announces appointment of Marc Princen as President of the EUCAN Business Unit

Marc Princen, Corporate Officer and President of the EUCAN (Europe and Canada) Business Unit, Takeda Pharmaceuticals International GmbH

Takeda Pharmaceutical Company Limited announced today that Marc Princen joined Takeda Pharmaceuticals International GmbH as Corporate Officer and President of the EUCAN (Europe and Canada) Business Unit. In his new role, Princen will lead all business operations in Europe and Canada, and he will report directly to Christophe Weber, the President and Chief Operating Officer of Takeda.

Marc Princen, Corporate Officer and President of the EUCAN (Europe and Canada) Business Unit, Takeda Pharmaceuticals International GmbH

“I am fully confident that Marc, with his rich set of skills and expertise both broadly across the pharmaceutical industry and specifically in a majority of Takeda’s therapeutic areas, will prove a great asset for Takeda,” said Christophe Weber, the President and Chief Operating Officer of Takeda. “His passion for healthcare and commitment to improving lives are in alignment with Takeda’s mission and core values of Takeda-ism, and we are pleased to bring such a well-rounded leader onboard.”

Princen brings more than 25 years of experience in the pharmaceutical industry including roles in a diverse array of functions such as commercial, marketing, business development and management across the globe, specifically, the United States, the Middle East and Africa, as well as several countries in Europe. Most recently, Princen served as President of the Mid-Europe Region at Merck based in Switzerland, and before that served as President and General Manager of Diversified Brands, a globe role focusing on branded generics, as well as the Regional President of Eastern Europe, Middle East, and Africa. Prior to Merck, Princen held a variety of senior leadership positions in the commercial, operational and marketing functions at Schering Plough.

Trevor Smith decided to leave Takeda and transition his professional home base to the United Kingdom after commuting to Zurich for several years. Smith will step down effective November 1, 2014 and will facilitate the transition of leadership until his departure from Takeda Pharmaceuticals International GmbH on March 31, 2015. Weber said, “Trevor’s legacy includes significant contributions such as newly establishing the Europe and Canada region at the time of the Nycomed integration, and driving the region’s business to become a diverse specialty care organization with a strong base in primary care.”